Ekso Bionics Holdings, Inc. (EKSO) CEO Thomas Looby Purchases 15,000 Shares of Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CEO Thomas Looby acquired 15,000 shares of the business’s stock in a transaction on Friday, September 8th. The stock was acquired at an average price of $1.13 per share, with a total value of $16,950.00. Following the transaction, the chief executive officer now owns 20,315 shares in the company, valued at approximately $22,955.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) opened at 1.27 on Wednesday. The firm has a 50-day moving average price of $1.53 and a 200 day moving average price of $2.24. Ekso Bionics Holdings, Inc. has a 12 month low of $0.99 and a 12 month high of $6.38. The company’s market cap is $32.75 million.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thestockobserver.com/2017/09/13/ekso-bionics-holdings-inc-ekso-ceo-thomas-looby-purchases-15000-shares-of-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Intellectus Partners LLC lifted its stake in shares of Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after acquiring an additional 5,294 shares during the last quarter. Independence Advisors LLC bought a new position in shares of Ekso Bionics Holdings in the 2nd quarter valued at $1,840,000. Carl Domino Inc lifted its stake in shares of Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after acquiring an additional 35,088 shares during the last quarter. National Planning Corp lifted its stake in shares of Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after acquiring an additional 126,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after acquiring an additional 176,197 shares during the last quarter. Institutional investors own 6.04% of the company’s stock.

Separately, Zacks Investment Research upgraded Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Wednesday, July 26th.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply